SAN DIEGO, Oct. 14 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced the formation of a new clinical advisory board focusing on retinal diseases and conditions. The initial three distinguished thought-leaders will provide guidance to Sequenom and Sequenom Center for Molecular Medicine (Sequenom CMM) regarding the development of retinal care molecular diagnostics.
Gregory S. Hageman, PhD – Dr. Hageman is the John A. Moran Presidential Professor of Ophthalmology and Visual Sciences at the University of Utah. He is a graduate of the University of Southern California, where he conducted both his undergraduate and graduate studies in biology and marine biology.
His primary research interest has been directed toward assessment of genes and pathways involved in the etiology of age-related macular degeneration (AMD), where he and his colleagues have been pioneers in providing a strong body of evidence that supports a role of variant genes in the etiology of this disease.
Prior to his recent move to the Moran Eye Center, Dr. Hageman served for three years as the Iowa Entrepreneurial Endowed Professor and Professor of Ophthalmology & Visual Sciences at the University of Iowa, Carver College of Medicine. At Iowa he directed the Cell Biology and Functional Genomics Laboratory. He held additional appointments as a Senior Member of the University of Iowa Center for Macular Degeneration, an Associate Faculty in the Center for the Study of Macular Degeneration, University of California, Santa Barbara, and Honorary Professorships at Queens University, Belfast, UK and Shandon
|SOURCE Sequenom, Inc.|
Copyright©2010 PR Newswire.
All rights reserved